Targaprimir-96 TFA 

Targaprimir-96 TFA is a potent inhibitor of microRNA-96 (miR-96) processing. Targaprimir-96 TFA selectively modulates miR-96 production in cancer cells and triggers apoptosis. Targaprimir-96 TFA binds primary miR-96 (pri-miR-96) with low nanomolar affinity. Targaprimir-96 TFA directly engages pri-miR-96 in breast cancer cells and is ineffective on healthy breast cells^[1].

Targaprimir-96 TFA shows a dose-response in MDA-MB-231 triple negative breast cancer cells with an IC₅₀ of ~50 nM by assessing the reduction of mature miR-96 levels. Targaprimir-96 (50 nM) TFA boosts the amount of the pri-miRNA and decreases the levels of the pre-miRNA and mature miRNA in a dose-dependent manner^[1].
Targaprimir-96 TFA (50 nM; 48 hours) increases FOXO1 levels and triggers apoptosis in breast cancer cell line 4175^[1].
Targaprimir-96 TFA binds RNA3 (contains both the Drosha site and the adjacent 1×1 nt GG internal loop) with a K_d of 85 nM. Targaprimir-96 binds RNA1, RNA2, RNA4, and RNA5 with K_d values of 1.2, 0.9, 1.2, and 1.5 μM, respectively. Thus, Targaprimir-96 TFA is highly RNA-selective and recognizes both the 1×1 nt GG and 1×1 nt UU loops to provide high affinity, effectively discriminating against a variety of related targets^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Targaprimir-96 TFA (10 mg/kg; i.p.; every other day for 21 days) inhibits tumor growth in a mouse model of triple-negative breast cancer (TNBC)^[1].
The amount of Targaprimir-96 (2 or 7 mg/kg; i.p.) in plasma peaks is ~4 h in FVB/n mice. Importantly, even 48 hours postinjection, the concentration of Targaprimir-96 TFA remaining in plasma is much greater than the 50 nM cellular concentration that triggered apoptosis: 1.6 μM for the 2 mg/kg dosage and 1.9 μM for the 7 mg/kg dosage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1505.77

C₇₉H₁₀₃F₃N₁₈O₉

OC(C(F)(F)F)=O.O=C(N)CN(C(CN(C(CN(C(CCCOC1=CC=CC(C2=NC3=CC=C(C4=NC5=CC=C(N6CCN(C)CC6)C=C5N4)C=C3N2)=C1)=O)CCC)=O)CCC)=O)CC7=CN(CCCNC(CCCOC8=C(C(C)(C)C)C=C(C9=NC%10=CC=C(N%11CCN(C)CC%11)C=C%10N9)C=C8C(C)(C)C)=O)N=N7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Velagapudi SP, et al. Design of a small molecule against an oncogenic noncoding RNA. Proc Natl Acad Sci U S A. 2016 May 24;113(21):5898-903.  [Content Brief]